From L-R: Arda Therapeutics chief technology officer Remi-Martin Laberge, CEO Adam Freund and CSO Scott Turner

Ex­clu­sive: Lil­ly backs a16z-fund­ed Ar­da Ther­a­peu­tic­s' $43M Se­ries A to take AD­Cs in­to fi­bro­sis

A three-year-old start­up based on decades of re­search in cell de­ple­tion is bet­ting that some of the hottest tools in on­col­o­gy may work even bet­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.